Maureen Galmes-Spit
VP Research Laigo Bio
Seminars
Thursday 12th March 2026
Developing Bispecific Antibody Degraders to Achieve Tissue-Specific Degradation of Membrane Proteins
10:50 am
- Engineering bispecific antibody degraders to enable selective, lysosomal degradation of target membrane proteins
- Pairing therapeutic targets with membrane E3 ligases to achieve tissue-specific degradation while sparing healthy tissues
- Expanding therapeutic reach to hard-to-drug and challenging membrane targets
New Data
Tuesday 10th March 2026
Designing Antibody-Based Degraders to Overcome ADC Limitations & Unlock New Therapeutic Opportunities for TPD
8:30 am
As antibody-derived degraders emerge as a powerful alternative to small molecules, this workshop will teach you how to engineer and optimise these biologics to unlock new extracellular degradation strategies.
We will cover:
- Exploring the evolution of extracellular targeted protein degradation, from early conceptual approaches to emerging IgG-based degrader architectures
- Comparing antibody-based degraders with small-molecule strategies to assess modality selection, E3 engagement, and translational trade-offs
- Addressing key in vivo challenges, including biodistribution, internalisation, and tissue selectivity, to optimise therapeutic index and clinical potential
This workshop is ideal for scientists exploring how antibody-derived scaffolds can extend targeted protein degradation beyond intracellular targets.
